

# Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass., Nov. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:

## **Jefferies 2022 London Healthcare Conference**

Format: Fireside chat

Date: Tuesday, November 15, 2022

Time: 3:35 a.m. ET / 8:35 a.m. GMT

## **Piper Sandler 34th Annual Healthcare Conference**

Format: Podium presentation

Date: Tuesday, November 29, 2022

Time: 11:30 a.m. ET

A live webcast of the presentation and fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, <http://investors.karyopharm.com/events-presentations>, and will be available for replay for 90 days following each event.

## **About Karyopharm Therapeutics**

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO<sup>®</sup> (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO<sup>®</sup>) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit [www.karyopharm.com](http://www.karyopharm.com), and follow us on Twitter at [@Karyopharm](https://twitter.com/Karyopharm) and [LinkedIn](https://www.linkedin.com/company/karyopharm).

XPOVIO<sup>®</sup> and NEXPOVIO<sup>®</sup> are registered trademarks of Karyopharm Therapeutics Inc.

SOURCE Karyopharm Therapeutics Inc.

For further information: Investors, Elhan Webb, CFA, Senior Vice President, Investor Relations, 617.658.0600, [elhan.webb@karyopharm.com](mailto:elhan.webb@karyopharm.com); Media, Sarah Connors, Vice President, Corporate Communications, 617.658.0600, [sarah.connors@karyopharm.com](mailto:sarah.connors@karyopharm.com)

---

<https://investors.karyopharm.com/2022-11-08-Karyopharm-to-Participate-at-Upcoming-Investor-Conferences>